AEON Biopharma, Inc. (AEON)
| Previous close | 1.7000 |
| Open | 1.7500 |
| Bid | 1.6800 x 800 |
| Ask | 1.7100 x 1100 |
| Day's range | 1.6300 - 1.8200 |
| 52-week range | 1.6300 - 17.1700 |
| Volume | |
| Avg. volume | 71,128 |
| Market cap | 65.194M |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3500 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
– Trial did not meet primary endpoint –IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet t
ZacksHere's Why AEON Biopharma, Inc. (AEON) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for AEON Biopharma, Inc. (AEON), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- GlobeNewswire
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
IRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Regarding a release issued under the same headline on March 29, 2024 by AEON Biopharma, Inc. (NYSE: AEON; AEON.WS), please note that in the first paragraph it incorrectly referenced March 29, 2024 as the Redemption Date. The Redemption Date is April 29, 2024. March 29, 2024 is the date on which the notice of redemption was delivered to warrant holders. The corrected release follows: AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Comp
